SPSarah Peisl

Sarah Peisl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Peisl has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modelling mechanisms and treatment of cholangiopathies with a bile duct on a chip

    by Henry William Hoyle, Anna Katharina Frank, Enya Amundsen-Isaksen, Sarah Peisl, Oline Øie Hovland, Jeremy Yeoh, Mughilan Selvarajah, Aleksandra Aizenshtadt, Kayoko Hirayama-Shoji, Fotios Sampaziotis, et al.

    Background and aims: Model systems for bile duct disorders are needed for testing therapeutic interventions. Current models have poor human relevance or limited potential for recreating the complex bile duct microenvironment at scale. We aimed to generate a humanized microphysiological system to model and treat cholangiopathies. Methods: An in vitro bile duct was created using 3D printed microfluidic chips containing a collagen-embedded canal seeded with patient-derived primary human cholangiocytes. Barrier permeability and compound transport across the epithelium was measured, and disruption of the barrier was performed with lipopolysaccharide treatment. The duct was challenged with the known hepatotoxicant Chlorpromazine. Biliatresone was used to model biliary-atresia and treated using N-acetyl-L-cysteine. Results: Cholangiocytes in the bile duct chip established a tight, polarized epithelial barrier. Verapamil and Linerixibat inhibited transport of rhodamine 123 and cholyl-lys-fluorescein respectively with 66 % (p = 0.0004) and 57 % (p = 0.03) reduction. 10 µg/mL lipopolysaccharide led to a loss of epithelial barrier integrity, measured by an increase of over 1000 % in leakage of both 3 kDa (p = 0.0002) and 10 kDa dextran (p = 0.0001) along with upregulation of cytokines. Chlorpromazine displayed dose-dependent toxicity with EC50 values of 84, 140 and 96 µM for three patient lines. Biliatresone induced a dose-dependent abnormal phenotype with loss of viability. The induced phenotype could be treated with N-acetyl-L-cysteine, improving viability from 23 % to 59 % (p < 0.0001) with treatment of 2 µg/mL Biliatresone. Conclusions: Our novel platform allows complex studies of bile duct biology, testing of off-target effects from drugs and treatment of a disease phenotype.

  • Open Access

    IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study

    by Claudia Mellenthin, Fabien Schaller, Lucie Vignot, Sarah Peisl, Rita Vesce, Irene Esposito, Carmen Gonelle-Gispert, Cornelia Schneider, Michel Adamina, Leo Hans Bühler

    Background: The proinflammatory cytokine interleukin 6 (IL-6) contributes to pancreatic tumorigenesis by activating the Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) signaling cascade. Targeting the IL-6/glycoprotein 130 (GP130)/JAK/STAT3 axis may therefore represent a promising therapeutic approach for pancreatic adenocarcinoma. Objective: This study investigates the activation of the IL-6/GP130/JAK/STAT3 pathway in archived biopsy samples from patients with pancreatic adenocarcinoma, quantifying its expression in both tumor and stromal compartments. In addition, potential associations between pathway activation and clinical outcomes are explored, including tumor stage, patient survival, and metabolic parameters such as diabetes, use of oral antidiabetic drugs, insulin therapy, and hemoglobin A 1c levels. Methods: We will conduct a retrospective cross-sectional analysis of patients with pancreatic adenocarcinoma treated at the Cantonal Hospital of Fribourg, Switzerland, between 2010 and 2025. Eligible cases are identified through tumor board records. Archived pathology specimens will be immunostained using a phospho-STAT3 antibody to assess GP130 receptor activation. The percentage of positively stained cells will be quantified separately for tumor tissue, stroma, and adjacent normal tissue using QPath software. Sample size calculations are based on the assumption that patients with higher IL-6 pathway activation have poorer prognoses. Detecting a 5% difference in activation requires 84 patients per group for 90% power or 104 per group for 95% power. Diabetes will be analyzed as a dichotomous variable, while IL-6/GP130/JAK/STAT3 activation will be treated as a continuous variable. Descriptive statistics will summarize pathway activation and clinical variables. Mean differences between groups will be compared, and survival outcomes will be evaluated using Cox proportional hazards models. Hazard ratios will be calculated for all metabolic parameters to assess potential associations between pathway activation and diabetes. All analyses will include 95% CIs, with missing data reported transparently. Results: This project is supported by a research grant from the Cantonal Hospital of Fribourg (HFR 2/2021 and 4/2022). It was approved by the Ethics Committee of Bern, Switzerland (project 2024‐01215). As of October 12, 2025, clinical records from 150 patients have been identified. Screening of additional patient records from 2024 to 2025 is ongoing. Conclusions: This study represents one of the first translational investigations of IL-6/GP130/JAK/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.


  • Open Access

    Prediction of postoperative infections by strategic data imputation and explainable machine learning

    by Hugo Guillen-Ramirez, Daniel Sanchez-Taltavull, Stéphanie Perrodin, Sarah Peisl, Karen Triep, Christophe Gaudet-Blavignac, Olga Endrich, Guido Beldi

    Objectives: Infections following healthcare-associated interventions drive patient morbidity and mortality, making early detection essential. Traditional predictive models utilize preoperative surgical characteristics. This study evaluated whether integrating postoperative laboratory values and their kinetics could improve outcome prediction. Materials and Methods: 91 794 surgical cases were extracted from electronic health records (EHR) and analyzed to predict bacterial infection as the endpoint. The endpoint was documented in the EHR as ICD-10 by a professional coding team. Variables were grouped as preoperative, intraoperative, or postoperative. Strategic imputation was used for postoperative missing laboratory values. Procedure-agnostic prediction models were built incorporating both static and kinetic properties of laboratory values. Results: The integration of kinetics of laboratory values into a machine learning predictor achieved a recall, precision and ROC AUC at postoperative day 2 of 0.71, 0.69, and 0.83, respectively. Moreover, infection detection outperformed clinician-based decision-making, as reflected by the postoperative timing of antibiotic administration. The analysis identified previously unknown, informative combinations of routine markers from hepatic, renal, and bone marrow functions that predict outcome. Discussion: Dynamic modelling of postoperative laboratory values enhanced the timeliness and accuracy of infection detection compared with static or preoperative-only models. The integration of explainable machine learning supports clinical interpretation and highlights the contribution of multiple organ systems to postoperative infection risk. Conclusion: A surgery-independent workflow integrating time-series values from laboratory parameters to enhance baseline predictors of infection. This interpretable approach is generalizable across procedures and has the potential to optimize patient outcomes and resource use in surgical care.


  • Open Access

    Noise in the operating room coincides with surgical difficulty

    by Sarah Peisl, Daniel Sánchez-Taltavull, Hugo Guillen-Ramirez, Franziska Tschan, Norbert K Semmer, Martin Hübner, Nicolas Demartines, Simon G Wrann, Stefan Gutknecht, Markus Weber, et al.

    Noise in the operating room has been shown to distract the surgical team and to be associated with postoperative complications. It is, however, unclear whether complications after noisy operations are the result of objective or subjective surgical difficulty or the consequence of distraction of the operating room team by noise. Noise level measurements were prospectively performed during operations in four Swiss hospitals. Objective difficulty for each operation was calculated based on surgical magnitude as suggested by the Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM), duration of operation and surgical approach. Subjective difficulty and distraction were evaluated by a questionnaire filled out by the operating room team members. Complications were assessed 30 days after surgery. Using regression analyses, the relationship between objective and subjective difficulty, distraction, intraoperative noise and postoperative complications was tested. Postoperative complications occurred after 121 (38%) of the 294 procedures included. Noise levels were significantly higher in operations that were objectively and subjectively more difficult (59.89 versus 58.35 dB(A), P < 0.001) and operations that resulted in postoperative complications (59.05 versus 58.77 dB(A), P = 0.004). Multivariable regression analyses revealed that subjective difficulty as reported by all members of the surgical team, but not distraction, was highly associated with noise and complications. Only objective surgical difficulty independently predicted noise and postoperative complications. Noise in the operating room is a surrogate of surgical difficulty and thereby predicts postoperative complications.


  • Influence of patient characteristics on microbial composition in surgical-site infections: insights from national surveillance study

    by Sarah Peisl, Hugo Guillen-Ramirez, Daniel Sánchez-Taltavull, Andreas Widmer, Rami Sommerstein, Guido Beldi

    Background: Although the impact of surgery- and patient-dependent factors on surgical-site infections (SSIs) have been studied extensively, their influence on the microbial composition of SSI remains unexplored. The aim of this study was to identify patient-dependent predictors of the microbial composition of SSIs across different types of surgery. Methods: This retrospective cohort study included 538 893 patients from the Swiss national infection surveillance programme. Multilabel classification methods, adaptive boosting and Gaussian Naive Bayes were employed to identify predictors of the microbial composition of SSIs using 20 features, including sex, age, BMI, duration of surgery, type of surgery, and surgical antimicrobial prophylaxis. Results: Overall, SSIs were recorded in 18 642 patients (3.8%) and, of these, 10 632 had microbiological wound swabs available. The most common pathogens identified in SSIs were Enterobacterales (57%), Staphylococcus spp. (31%), and Enterococcus spp. (28%). Age (mean feature importance 0.260, 95% c.i. 0.209 to 0.309), BMI (0.224, 0.177 to 0.271), and duration of surgery (0.221, 0.180 to 0.269) were strong and independent predictors of the microbial composition of SSIs. Increasing age and duration of surgical procedure as well as decreasing BMI were associated with a shift from Staphylococcus spp. to Enterobacterales and Enterococcus spp. An online application of the machine learning model is available for validation in other healthcare systems. Conclusion: Age, BMI, and duration of surgery were key predictors of the microbial composition of SSI, irrespective of the type of surgery, demonstrating the relevance of patient-dependent factors to the pathogenesis of SSIs.


  • Open Access

    Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature

    by Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bühler, Bernhard Egger

    Background/Objectives: Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival. Therefore, novel biomarkers and therapeutic targets are needed. In the present review, we performed a comprehensive summary of therapeutic approaches targeting the GP130/JAK/STAT3 pathway. Methods: We systematically reviewed the PubMed and Embase databases for preclinical and clinical studies, from inception to October 4, 2020, on drugs targeting the GP130/JAK/STAT3 pathway. Bias assessments and qualitative analyses were performed. Results: Twenty-five preclinical and nine clinical trials were included in the review. All preclinical studies reported a favorable outcome in terms of pancreatic ductal adenocarcinoma progression. Futhermore, drugs targeting the GP130/JAK/STAT3 pathway were shown to be efficient chemosensitizers. However, high publication bias was assumed. In the clinical setting, bazedoxifene and itacitinib improved patient outcomes. Conclusion: Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in the treatment of pancreatic ductal adenocarcinoma and that these molecules are effective chemosensitizers. Though only a few trials have shown the efficacy in a clinical setting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic ductal adenocarcinoma and may help overcome chemotherapy resistance.


  • Open Access

    Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg

    by Sarah Peisl, Stefan Zimmermann, Bertrand Camey, Daniel Betticher, Christine Bouchardy

    Breast cancer screening mammography is widespread in industrialised countries within the framework of public health program or opportunist form. Only few data exist on the comparison of effectiveness between organised and opportunistic screening. The aim of this study is to compare organised and opportunistic screening using population-based data from the Fribourg cancer registry, Switzerland. We included all first primary breast adenocarcinoma diagnosed between 2006 and 2014 in women aged 50–69 years resident in the canton of Fribourg. We considered only breast cancer discovered by mammography screening. We compared patients, tumour characteristics and treatment modalities between breast cancer detected by the organised screening program versus opportunistic screening using logistic regression. Out of 989 patients diagnosed with breast cancer, 402 (40.6%) were diagnosed by organised and 205 (20.7%) by opportunistic screening. Women with breast cancer detected within the screening program were more likely to be from rural areas (P = 0.035) and lived less frequently in high favoured regions (P = 0.020). They presented more frequently in situ than invasive cancer (P = 0.022). For patients with invasive breast cancer, those detected by the program were less likely to undergo mastectomy (P = 0.06) and consequently, they were more likely to undergo radiation therapy (P = 0.003). Adjustment for area of residence and financial context of the region did not modify the results presented. The present study reports an increased rate of detection of carcinoma in situ in organised screening program as compared to opportunistic screening mammographies, an indirect evidence of a higher radiologic sensitivity. Furthermore, the results show a trend towards more mastectomies among patients with breast cancer discovered after opportunistic than after organized mammography screening, reflecting lower treatment burden. Those results were independent of socio-economic factors which differed across screening groups.